Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity

Fatih Kıvrakoğlu; Mustafa Ergin; Serdar Kayıhan; Hanife Uzar; Zahide Şimşek; İlhami Yüksel

doi:10.38053/acmj.1989511

Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity

Abstract

Aims: This investigation sought to evaluate the potential associations between circulating A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-7, and ADAMTS-12 protein concentrations and the degree of structural hepatic fibrosis observed in patients with chronic hepatitis B (CHB). Methods: This retrospective descriptive study included a cohort of 77 patients diagnosed with CHB, alongside 30 age-matched healthy participants. We utilized a sandwich enzyme-linked immunosorbent assay methodology to quantify the serum concentrations of both ADAMTS-7 and ADAMTS-12 in all study subjects. Fibrosis stage was assessed through liver biopsy, graded by the Ishak scoring system. Statistical analyses were conducted to compare groups and to evaluate the correlation between biomarker levels and fibrosis stage. Results: Compared with the healthy control group, patients with CHB exhibited significantly reduced serum concentrations of ADAMTS-7 and ADAMTS-12. However, no significant differences emerged between mild and advanced fibrosis. Conclusion: Serum ADAMTS-7 and ADAMTS-12 levels are significantly reduced in patients with CHB compared to healthy controls. However, since they do not differentiate between mild and advanced fibrosis, they have limited clinical utility as non invasive biomarkers for staging fibrosis severity. These reductions may reflect a generalized response to chronic viral infection rather than the specific extent of fibrotic tissue.

Keywords

Supporting Institution

Financial support for the ELISA kits utilized in this research was provided by the Scientific Research Projects (BAP) unit of Ankara Dışkapı Training and Research Hospital.

Ethical Statement

Approval for this research was obtained from the Ethics Committee of xxx before study procedures were conducted (Decision No: 30/04; approval date: May 30, 2016).

Thanks

The authors would like to express their sincere gratitude to Dr. Yusuf Coşkun and Dr. Hakan Akıncı for their valuable contributions to the preparation and publication of this study.

References

Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol. 2014;20(33):11595-11617. doi:10.3748/wjg.v20.i33.11595
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-583. doi:10.1016/j.jhep.2025.03.018
Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377(8):756-768. doi:10.1056/NEJMra1610570
European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update. J Hepatol. 2021;75(3):659-689. doi:10.1016/j.jhep.2021.05.025
Akhan S, Aynıoğlu A, Çağatay A, et al. Kronik hepatit B virusu infeksiyonunun yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu uzlaşı raporu. Klimik Derg. 2014;27(Suppl 1):2-18. doi:10.5152/kd.2014.26
Yu H, Zhu Y. Expression of ADAMTS-7 and ADAMTS-12 in the nucleus pulposus during degeneration of rat caudal intervetebral disc. J Vet Med Sci. 2012;74(1):9-15. doi:10.1292/jvms.10-0556
Gao YX, Yu CA, Lu JH, et al. ADAMTS-7 expression increases in the early stage of angiotensin II-induced renal injury in elderly mice. Kidney Blood Press Res. 2013;38(1):121-131. doi:10.1159/000355758

Gökdemir İE, Özdeğirmenci Ö, Elmas B, et al. Evaluation of ADAMTS12, ADAMTS16, ADAMTS18 and IL-33 serum levels in pre-eclampsia. J Matern Fetal Neonatal Med. 2016;29(15):2451-2456. doi:10.3109/14767058.2015.1087497
Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699. doi:10.1016/0168-8278(95)80226-6
Sterling RK, King WC, Wahed AS, et al. Evaluating noninvasive markers to identify advanced fibrosis by liver biopsy in HBV/HIV co-infected adults. Hepatology. 2020;71(2):411-421. doi:10.1002/hep.30825
Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151-166. doi:10.1038/s41575-020-00372-7
Kelwick R, Desanlis I, Wheeler GN, Edwards DR. The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. Genome Biol. 2015;16(1):113. doi:10.1186/s13059-015-0676-3
Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. doi:10.1016/j.mam.2018.09.002
Wong GL, Lemoine M. The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines. J Hepatol. 2025;82(5):918-925. doi:10.1016/j.jhep.2024.12.004
Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292-302. doi:10.1002/hep.27382
Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. doi:10.1038/nrdp.2018.35
Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014;20(10):2595-2605. doi:10.3748/wjg.v20.i10.2595
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-686. doi:10.1053/j.gastro.2005.11.016

Details

Primary Language

English

Subjects

Gastroenterology and Hepatology

Journal Section

Research Article

Authors

Fatih Kıvrakoğlu ^*
0000-0002-5388-794X
Türkiye

Mustafa Ergin
0000-0002-9593-3705
Türkiye

Serdar Kayıhan
0000-0001-6296-2588
Türkiye

Hanife Uzar
0000-0003-4358-5777
Türkiye

Zahide Şimşek
0000-0003-0212-064X
Türkiye

İlhami Yüksel
0000-0002-9730-2309
Türkiye

Publication Date

September 11, 2026

Submission Date

July 7, 2026

Acceptance Date

August 24, 2026

Published in Issue

Year 2026 Volume: 8 Number: 5

DOI

https://doi.org/10.38053/acmj.1989511

IZ

https://izlik.org/JA48CE66NH

Cite

RIS / Bibtex

APA

Kıvrakoğlu, F., Ergin, M., Kayıhan, S., Uzar, H., Şimşek, Z., & Yüksel, İ. (2026). Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity. Anatolian Current Medical Journal, 8(5), 1075-1080. https://doi.org/10.38053/acmj.1989511

AMA

1.Kıvrakoğlu F, Ergin M, Kayıhan S, Uzar H, Şimşek Z, Yüksel İ. Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity. Anatolian Curr Med J / ACMJ / acmj. 2026;8(5):1075-1080. doi:10.38053/acmj.1989511

Chicago

Kıvrakoğlu, Fatih, Mustafa Ergin, Serdar Kayıhan, Hanife Uzar, Zahide Şimşek, and İlhami Yüksel. 2026. “Serum A Disintegrin and Metalloproteinase With Thrombospondin Motifs-7 and 12 Levels Are Reduced in Chronic Hepatitis B But Do Not Distinguish Fibrosis Severity”. Anatolian Current Medical Journal 8 (5): 1075-80. https://doi.org/10.38053/acmj.1989511.

EndNote

Kıvrakoğlu F, Ergin M, Kayıhan S, Uzar H, Şimşek Z, Yüksel İ (September 1, 2026) Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity. Anatolian Current Medical Journal 8 5 1075–1080.

IEEE

[1]F. Kıvrakoğlu, M. Ergin, S. Kayıhan, H. Uzar, Z. Şimşek, and İ. Yüksel, “Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity”, Anatolian Curr Med J / ACMJ / acmj, vol. 8, no. 5, pp. 1075–1080, Sept. 2026, doi: 10.38053/acmj.1989511.

ISNAD

Kıvrakoğlu, Fatih - Ergin, Mustafa - Kayıhan, Serdar - Uzar, Hanife - Şimşek, Zahide - Yüksel, İlhami. “Serum A Disintegrin and Metalloproteinase With Thrombospondin Motifs-7 and 12 Levels Are Reduced in Chronic Hepatitis B But Do Not Distinguish Fibrosis Severity”. Anatolian Current Medical Journal 8/5 (September 1, 2026): 1075-1080. https://doi.org/10.38053/acmj.1989511.

JAMA

1.Kıvrakoğlu F, Ergin M, Kayıhan S, Uzar H, Şimşek Z, Yüksel İ. Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity. Anatolian Curr Med J / ACMJ / acmj. 2026;8:1075–1080.

MLA

Kıvrakoğlu, Fatih, et al. “Serum A Disintegrin and Metalloproteinase With Thrombospondin Motifs-7 and 12 Levels Are Reduced in Chronic Hepatitis B But Do Not Distinguish Fibrosis Severity”. Anatolian Current Medical Journal, vol. 8, no. 5, Sept. 2026, pp. 1075-80, doi:10.38053/acmj.1989511.

Vancouver

1.Fatih Kıvrakoğlu, Mustafa Ergin, Serdar Kayıhan, Hanife Uzar, Zahide Şimşek, İlhami Yüksel. Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity. Anatolian Curr Med J / ACMJ / acmj. 2026 Sep. 1;8(5):1075-80. doi:10.38053/acmj.1989511